MULTİPLE SKLEROZ ALT GRUPLARI ARASINDAKİ AKIMA BAĞLI DİLATASYON ÖLÇÜMLERİNDEKİ FARKLILIKLAR

Öz

AMAÇ: Multiple skleroz (MS) alt grupları ile normal kontrol grubu arasındaki akıma bağlı dilatasyon (ABD) ölçümlerindeki farklılıkları göstermeyi amaçladık.
GEREÇ VE YÖNTEM: Çalışmaya 96 katılımcı (ortalama yaş: 42,7 ± 14,1 yıl) alındı. Katılımcıları şu şekilde gruplandırdı: 47 MS hastası (ortalama yaş: 40,2 ± 12,2 yıl) ve 49 normal kontrol grubu (ortalama yaş: 45,22 ± 15,27). MS hastaları şu şekilde alt sınıflara ayrıldı: Grup 1 – Tekrarlayan ve düzelen MS (Relapsing-remitting) (RRMS): 37 hasta (ortalama yaş: 36,9 ± 11,2); Grup 2 – İkincil İlerleyici MS (Sekonder Progressif) (SPMS): 5 hasta (ortalama yaş: 49,0 ± 6,0); Grup 3 – Birincil İlerleyici MS (Primer Progressif) (PPMS): 5 hasta (ortalama yaş: 55,4 ± 10,6 yıl). Brakial arterin shear strese verdiği tepkiyi ve periferik vazodilatör nitrik oksit (NO) üretim kapasitesini akıma bağlı dilatasyon yöntemini kullanarak değerlendirdik.
BULGULAR: Normal kontrol grubu ile MS alt grupları arasında akıma bağlı bazal, akıma bağlı hiperemi ve akıma bağlı bazal/hiperemi değerleri açısından istatistiksel olarak anlamlı farklar vardı (sırasıyla p = 0,001, p = 0,029 ve p = 0,020). Yaş ve cinsiyet faktörleri istatistiksel olarak kontrol edildiğinde, genişletilmiş özürlülük durumu ölçeği (EDSS) puanları ile diğer ölçümler arasında korelasyon bulunmadı (p > 0,05).
SONUÇ: Verilerimiz MS hastalarında ABD ölçümlerinin normal kontrollere göre daha fazla azaldığını göstermektedir. Birincil İlerleyici MS grubu, diğer gruplara kıyasla ABD ölçümleri açısından daha şiddetli bozulma gösterdi. ABD bazal/hiperemi oranı değerleri, normal kontrol ve tekrarlayan ve düzelen MS gruplarına kıyasla ilerleyici MS gruplarında daha fazla azaldı.

Anahtar Kelimeler

• Nitrik oksid
• Multiple skleroz
• Vasküler endotel-bağımlı gevşeme.

DIFFERENCES IN FLOW-MEDIATED DILATATION MEASUREMENTS BETWEEN MULTIPLE SCLEROSIS SUBGROUPS

Öz

OBJECTIVE: We aimed to show the differences in flow-mediated dilatation (FMD) measurements between multiple sclerosis (MS) subgroups and normal control participants.
MATERIAL AND METHODS: There were 96 participants (mean age: 42.7 ± 14.1 years) in this study. We grouped the participants as follows: 47 MS patients (mean age: 40.2 ± 12.2 years) and 49 normal control participants (mean age: 45.22 ± 15.27). The MS patients were subclassified as follows: Group 1 – relapsing-remitting multiple sclerosis (RRMS): 37 patients (mean age: 36.9 ± 11.2); Group 2 – secondary progressive multiple sclerosis (SPMS): 5 patients (mean age: 49.0 ± 6.0); and Group 3 – primary progressive multiple sclerosis (PPMS): 5 patients (mean age: 55.4 ± 10.6 years). We used FMD methods for an indirect evaluation of the brachial artery’s reaction to shear stress and peripheral vasodilatory nitric oxide (NO) production capability.
RESULTS: There were statistically significant differences between the normal control group and the MS subgroups regarding flow-mediated basal, flow-mediated hyperemia, and FMD ratio values (p = 0.001, p = 0.029, and p = 0.020, respectively). No correlation was found between the expanded disability status scale (EDSS) scores and other measurements after statistically controlling for age and gender factors (p > 0.05).
CONCLUSIONS: Our data indicate that FMD measurements decreased more in the MS patients compared to the normal controls. The PPMS group exhibited more severe deterioration with regard to FMD measures than the other groups. FMD ratio values decreased more in the progressive MS groups compared to the normal control and RRMS groups.

Anahtar Kelimeler

• Nitric Oxide
• Multiple Sclerosis
• Vascular Endothelium-Dependent Relaxation.

Kaynakça

1. 1. López-Gambero AJ, Sanjuan C, Serrano-Castro PJ, et al. The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases. Biomedicines. 2020;8(9):295.
2. 2. Lane J, Ng HS, Poyser C, et al. Multiple sclerosis incidence: A systematic review of change over time by geographical region. Mult Scler Relat Disord. 2022;63:103932.
3. 3. Correale J, Marrodan M, Ysrraelit MC. Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis. Biomedicines. 2019;7(1):14.
4. 4. Bennett J, Basivireddy J, Kollar A, et al. Blood-brain barrier disruption and enhanced vascular permeability in the multiplesclerosis model EAE. J Neuroimmunol. 2010;229(1-2):180-91.
5. 5. Islam MT. Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders. Neurol Res. 2017 ;39(1):73-82.
6. 6. Ghafourifar P, Mousavizadeh K, Parihar MS, et al. Mitochondria in multiple sclerosis. Front Biosci. 2008;13:3116- 26.
7. 7. Knight JA. Reactive oxygen species and the neurodegenerative disorders. AnnClin Lab Sci. 1997;27(1):11-25.
8. 8. Emerit J, Edeas M, Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed Pharmacother. 2004;58(1):39-46.

9. 9. Kaplan TB, Berkowitz AL, Samuels MA. Cardiovascular Dysfunction in MultipleSclerosis. Neurologist. 2015;20(6):108-14.
10. 10. Brandner J, Lu H, Muller O, et al. Cardiogenic shock due to reverse takotsubo syndrome triggered by multiplesclerosis brainstem lesions: a case report and mini review. Front Cardiovasc Med. 2023;10:1175644.
11. 11. Bayer AD, Cahill JF, Rizvi SA. Multiple sclerosis relapse presenting as an acute cardiomyopathy. Mult Scler Relat Disord. 2019 ;27:7-8.
12. 12. Ramphul K, Kumar N, Verma R, et al. Acute myocardial infarction in patients with multiple sclerosis; An insight from 1785 cases in the United States. Mult Scler Relat Disord. 2022;68:104140.
13. 13. Doskas T, Dardiotis E, Vavougios GD, et al. Stroke riskin multiple sclerosis: a critical appraisal of the literature. Int J Neurosci. 2023;133(10):1132-1152.
14. 14. Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. Nitric Oxide. 2001;5(2):88-97.
15. 15. Davel AP, Wenceslau CF, Akamine EH, et al. Endothelial dysfunction in cardiovascular and endocrine- metabolic diseases:an update. Braz J Med Biol Res. 2011;44(9):920-32.
16. 16. Cyr AR, Huckaby LV, Shiva SS, Zuckerbraun BS. Nitric Oxide and Endothelial Dysfunction. Crit Care Clin. 2020;36(2):307-21.
17. 17. Danilov AI, Andersson M, Bavand N, et al. Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis. J Neuroimmunol. 2003;136(12):112-8.
18. 18. Senzaki K, Okada Y, Ochi H, et al. Vascular endothelial dysfunction associated with severity in multiple sclerosis. Mult Scler Relat Disord. 2021;54:103135.
19. 19. DuBose NG, DeJonge SR, Jeng B, Motl RW. Vascular dysfunction in multiple sclerosis: Scoping review of current evidence for informing future research directions. Mult Scler Relat Disord. 2023;78:104936.
20. 20. Higashi Y. Assessment of endothelial function history, methodological aspects, and clinical perspectives. International heart journal. 2015;56(2):125-34.
21. 21. Ras RT, Streppel MT, Draijer R, et al. Flow-mediated dilation and cardiovascular risk prediction: a systematic review with meta-analysis. International journal of cardiology. 2013;168(1):344-51.
22. 22. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circulation research. 2000;87(10), 840-4.
23. 23. Hayward CS, Kraidly M, Webb C M, et al. Assessment of endothelial function using peripheral wave form analysis: a clinical application. Journal of the American College of Cardiology. 2002;40(3), 521-8.
24. 24. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-73.
25. 25. Meyer-Moock S, Feng YS, Maeurer M, et al. Systematic literaturereview and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients withmultiple sclerosis. BMC Neurol. 2014;14:58.
26. 26. Widmer RJ, Lerman A. Endothelial dysfunction and cardiovascular disease. Glob Cardiol Sci Pract. 2014;(3): 291–308.
27. 27. Pétrault O, Pétrault M, Ouk T, et al. Visceral adiposity links cerebrovascular dysfunction to cognitive impairment in middle-aged mice. Neurobiol Dis. 2019;130:104536.
28. 28. Saito H, Kobayashi K, Mochizuki H, Ishii T. Axonal degeneration of the peripheral nerves and postganglionic an hidrosis in a patient with multiple sclerosis. Tohoku J Exp Med. 1990 ;162(3):279-91.
29. 29. Matsuo A, Akiguchi I, Lee GC, et al. Myelin degeneration in multiple system atrophy detected by unique antibodies. Am J Pathol. 1998;153(3):735-44.
30. 30. Wunsch M, Jabari S, Voussen B, et al. The enteric nervous system is a potential autoimmune target in multiple sclerosis. Acta Neuropathol. 2017;134(2):281-95.